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1. INTRODUCTION 
Diabetes Mellitus (DM) 
           The Diabetes Mellitus is chronic metabolic disorder, which there are 
high blood sugar level over a prolonged period. The term "mellitus" or "from honey" 
was added by the Briton John Rolle in the late 1700s to separate the condition 
from diabetes insipidus, which is also associated with frequent urination. It is a fast-
growing global problem with huge social, health and economic consequences. It is 
estimated that in 2010 there were globally 285 million people (approximately 6.4% of 
the adult population) suffering from this disease. This number is estimated to increase 
to 430 million in the absence of better control or cure. An ageing population and 
obesity are two main reasons for the increase. Furthermore it has been shown that 
almost 50% of the putative diabetics are not diagnosed until 10 years after onset of the 
disease, hence the real prevalence of global diabetes must be astronomically high.  
This high blood sugar produces the symptoms of frequent urination, increased 
thirst, and increased hunger. Untreated, diabetes can cause many 
complications. Acute complications include diabetic ketoacidosis and non ketotic 
hyperosmolarcoma. Serious long-term complications include heart disease, stroke, 
kidney failure, foot ulcers and damage to the eyes.  
Indian physicians around the same time identified the disease and classified it 
as Madhumeha or "honey urine", noting but the urine would attract ants. This is 
possibly due to the diet and life-style of the ancient people, or because the clinical 
symptoms were observed during the advanced stage of the disease. Galen named the 
disease "Diarrhea of the urine" (diarrhea urinosa). The earliest surviving work with a 
detailed reference to diabetes is that of Aretaeus of Cappadocia (2nd or early 3rd 
century CE). Type 1 and type 2 diabetes were identified as separate conditions for the 
first time by the Indian physicians Sushruta and Charaka in 400-500 CE with type 1 
associated with youth and type 2 with being overweight. Effective treatment was not 
developed until the early part of the 20th century, when Canadians Frederick 
Banting and Charles Herbert Best isolated and purified insulin in 1921 and 1922.  This 
was followed by the development of the long-acting insulin NPH in the 1940s.  
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Signs and Symptoms 
 
Fig No:1- Main Symptoms of Diabetes  
Overview of the most significant symptoms of diabetes 
The classic symptoms of untreated diabetes are weight loss, polyuria (frequent 
urination), polydipsia (increased thirst), and polyphagia (increased hunger). 
Symptoms may develop rapidly (weeks or months) in type 1 diabetes, while they 
usually develop much more slowly and may be subtle or absent in type 2 diabetes. 
Several other signs and symptoms can mark the onset of diabetes, although 
they are not specific to the disease. In addition to the known ones above, they include 
blurry vision, headache, fatigue, slow healing of cuts, and itchy skin. Prolonged high 
blood glucose can cause glucose absorption in the lens of the eye, which leads to 
changes in its shape, resulting in vision changes. A number of skin rashes that can 
occur in diabetes are collectively known as diabetic dermadromes. 
People (usually with type 1 diabetes) may also experience episodes of diabetic 
ketoacidosis, a type of metabolic problems characterized by nausea, vomiting 
and abdominal pain, the smell of acetone on the breath, deep breathing known 
as Kussmaul breathing, and in severe cases a decreased level of consciousness. A rare 
but equally severe possibility is hyperosmolar nonketotic state, which is more 
common in type 2 diabetes and is mainly the result of dehydration. 
  
Department of Pharmacology                    3                  J.K.K. Nattraja College Of Pharmacy    
 
Complications 
All forms of diabetes increase the risk of long-term complications. These 
typically develop after many years (10–20), but may be the first symptom in those 
who have otherwise not received a diagnosis before that time. 
The major long-term complications relate to damage to blood vessels. 
Diabetes doubles the risk of cardiovascular disease and about 75% of deaths in 
diabetics are due to coronary artery disease. Other "macrovascular" 
diseases are stroke, and peripheral vascular disease. 
The primary micro vascular complications of diabetes include damage to the 
eyes, kidneys, and nerves. Damage to the eyes, known as diabetic retinopathy, is 
caused by damage to the blood vessels in the retina of the eye, and can result in 
gradual vision loss and potentially blindness. Damage to the kidneys, known 
asdiabetic nephropathy, can lead to tissue scarring, urine protein loss, and 
eventually chronic kidney disease, sometimes requiring dialysis or kidney transplant. 
Damage to the nerves of the body, known as diabetic neuropathy, is the most common 
complication of diabetes. The symptoms can include numbness, tingling, pain, and 
altered pain sensation, which can lead to damage to the skin. Diabetes-related foot 
problems (such as diabetic foot ulcers) may occur, and can be difficult to treat, 
occasionally requiring amputation. Additionally, proximal diabetic neuropathy causes 
painful muscle wasting and weakness. 
There is a link between cognitive deficit and diabetes. Compared to those 
without diabetes, those with the disease have a 1.2 to 1.5-fold greater rate of decline 
in cognitive function. 
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Diagnosis 
Diabetes mellitus is characterized by recurrent or persistent hyperglycemia, 
and is diagnosed by demonstrating any one of the following:  
 Fasting plasma glucose level ≥ 7.0 mmol/l (126 mg/dl) 
 Plasma glucose ≥ 11.1 mmol/l (200 mg/dl) two hours after a 75 g oral glucose 
load as in a glucose tolerance test 
 Symptoms of hyperglycemia and casual plasma glucose ≥ 11.1 mmol/l 
(200 mg/dl) 
 Glycated hemoglobin (Hb A1C) ≥ 6.5%. 
A positive result, in the absence of unequivocal hyperglycemia, should be confirmed 
by a repeat of any of the above methods on a different day. It is preferable to measure 
a fasting glucose level because of the ease of measurement and the considerable time 
commitment of formal glucose tolerance testing, which takes two hours to complete 
and offers no prognostic advantage over the fasting test. According to the current 
definition, two fasting glucose measurements above 126 mg/dl (7.0 mmol/l) is 
considered diagnostic for diabetes mellitus. 
Per the World Health Organization people with fasting glucose levels from 6.1 
to 6.9 mmol/l (110 to 125 mg/dl) are considered to have impaired fasting glucose. 
People with plasma glucose at or above 7.8 mmol/l (140 mg/dl), but not over 
11.1 mmol/l (200 mg/dl), two hours after a 75 g oral glucose load are considered to 
haveimpaired glucose tolerance. Of these two prediabetic states, the latter in particular 
is a major risk factor for progression to full-blown diabetes mellitus, as well as 
cardiovascular disease. The American Diabetes Association since 2003 uses a slightly 
different range for impaired fasting glucose of 5.6 to 6.9 mmol/l (100 to 125 mg/dl). 
Glycated hemoglobin is better than fasting glucose for determining risks of 
cardiovascular disease and death from any cause.  
The rare disease diabetes insipidus has similar symptoms to diabetes mellitus, 
but without disturbances in the sugar metabolism (insipidus means "without taste" in 
Latin) and does not involve the same disease mechanisms. 
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WHO Diabetes Diagnostic Criteria  
Condition 
2 hour 
glucose 
Fasting glucose HbA1c 
Unit 
mmol/l(mg/dl
) 
mmol/l(mg/dl) % 
Normal <7.8 (<140) <6.1 (<110) <6.0 
Impaired fasting glycaemia  <7.8 (<140) 
≥ 6.1(≥110) & 
<7.0(<126) 
6.0–6.4 
Impaired glucose tolerance  ≥7.8 (≥140) <7.0 (<126) 6.0–6.4 
Diabetes mellitus ≥11.1 (≥200) ≥7.0 (≥126) ≥6.5 
Prevention and Treatment 
There is no known preventive measure for type 1 diabetes. Type 2 diabetes 
can often be prevented by a person being a normal body weight, physical exercise, 
and following a healthy diet. Dietary changes known to be effective in helping to 
prevent diabetes include a diet rich in whole grains and fiber, and choosing good fats, 
such as polyunsaturated fats found in nuts, vegetable oils, and fish. Limiting sugary 
beverages and eating less red meat and other sources of saturated fatcan also help in 
the prevention of diabetes.  Active smoking is also associated with an increased risk of 
diabetes, so smoking cessation can be an important preventive measure as well.  
 
 
  
Department of Pharmacology                    6                  J.K.K. Nattraja College Of Pharmacy    
 
Diabetes mellitus is a chronic disease, for which there is no known cure except 
in very specific situations. Management concentrates on keeping blood sugar levels as 
close to normal ("euglycemia") as possible, without causing hypoglycemia. This can 
usually be accomplished with diet, exercise, and use of appropriate medications 
(insulin in the case of type 1 diabetes; oral medications, as well as possibly insulin, in 
type 2 diabetes). 
Learning about the disease and actively participating in the treatment is vital 
for people with diabetes, since the complications of diabetes are far less common and 
less severe in people who have well-managed blood sugar levels. The goal of 
treatment is an HbA1C level of 6.5%, but should not be lower than that, and may be 
set higher.  Attention is also paid to other health problems that may accelerate the 
deleterious effects of diabetes. These include smoking, elevated cholesterol levels, 
obesity, high blood pressure, and lack of regular exercise. Specialised footwear is 
widely used to reduce the risk of ulceration, or re-ulceration, in at-risk diabetic feet. 
Lifestyle: 
People with diabetes can benefit from education about the disease and 
treatment, good nutrition to achieve a normal body weight, and sensible exercise, with 
the goal of keeping both short-term and long-term blood glucose levels within 
acceptable bounds. In addition, given the associated higher risks of cardiovascular 
disease, lifestyle modifications are recommended to control blood pressure.  
Medications: 
Metformin is generally recommended as a first line treatment for type 2 
diabetes, as there is good evidence that it decreases mortality. Routine use of aspirin, 
however, has not been found to improve outcomes in uncomplicated diabetes. 
Angiotensin converting enzyme inhibitors (ACEIs) improve outcomes in those with 
DM while the similar medications angiotensin receptor blockers (ARBs) do not.  
Type 1 diabetes is typically treated with a combinations of regular and 
NPH insulin, or synthetic insulin analogs. When insulin is used in type 2 diabetes, a 
long-acting formulation is usually added initially, while continuing oral medications.  
Doses of insulin are then increased to effect.  
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In those with diabetes some recommend blood pressure levels below 
120/80 mmHg;  however, evidence only supports less than or equal to somewhere 
between 140/90 mmHg to 160/100 mmHg.  
Pancreatic transplantation: 
A pancreas transplant is occasionally considered for people with type 1 
diabetes who have severe complications of their disease, including end stage renal 
diseaserequiring kidney transplantation. 
Support: 
In countries using a general practitioner system, such as the United Kingdom, 
care may take place mainly outside hospitals, with hospital-based specialist care used 
only in case of complications, difficult blood sugar control, or research projects. In 
other circumstances, general practitioners and specialists share care in a team 
approach. Home telehealth support can be an effective management technique. 
Diets And Exercise Treatment 
Making healthy food choices is very important to help keep your blood 
glucose level under control. People with diabetes don't need to buy or prepare special 
foods. The foods that are best for someone with diabetes are excellent choices for 
everyone: foods that are low in fat, salt, and sugar, and high in fiber, such as beans, 
fruits, vegetables, and whole grains. These foods help you reach and stay at a weight 
that's good for your body. Regular physical activity is important for people with 
diabetes. Being physically active has been shown to improve blood glucose levels in 
older people whose levels are high. Exercise is especially good for people with 
diabetes because it helps control weight, helps insulin work better to lower blood 
glucose, is good for your heart and lungs, gives you more energy,  Regular physical 
activity improves insulin resistance and lipid profile (reduction in triglyceride and 
increase in high-density lipoprotein (HDL)) and lowers blood pressure (although 
blood pressure will rise during exercise),the metabolic benefits in type 2 diabetes are 
lost within 3-10 days of stopping regular exercise, physical activity also protects 
against the development of type 2 diabetes. 
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A1C Test 
The A1C test is used to detect type 2 diabetes and prediabetes but is not 
recommended for diagnosis of type 1 diabetes or gestational diabetes. The A1C test is 
a blood test that reflects the average of a person’s blood glucose levels over the past 3 
months and does not show daily fluctuations. The A1C test is more convenient for 
patients than the traditional glucose tests because it does not require fasting and can 
be performed at any time of the day.The A1C test result is reported as a percentage. 
The higher the percentage, the higher a person’s blood glucose levels have been. A 
normal A1C level is below 5.7 percent.An A1C of 5.7 to 6.4 percent indicates 
prediabetes. People diagnosed with prediabetes may be retested in 1 year. People with 
an A1C below 5.7 percent maystill be at risk for diabetes, depending on the presence 
of other characteristics that put them at risk, also known as risk factors. People with 
an A1C above 6.0 percent should be considered at very high risk of developing 
diabetes. A level of 6.5 percent or above means a person has diabetes. 
Herbal drugs 
Allopathic medicines are very costly. In contrast, herbal medicines are very 
cheap. This cost effectiveness makes them all the more alluring.Herbal medicines can 
be brought without prescription and they are available in all most all health stores. 
Some herbs can even be grown at home.For certain ailments, herbal medicines are 
considered to be more effective than allopathic medicines. 
Herbal medicines do not have any side effects, as they are free from 
chemicals. They are also milder than allopathic medicines.The natural detoxification 
process of the body is effectively enhanced by herbal medicines. They can be used to 
cleanse the colon, improve digestion and food absorption. Herbal medicines are also 
very good in boosting the immune system. 
Herbal medicines are very effective in curing various digestive disorders like 
colitis, indigestion, peptic ulcers, and irregular bowel movements.These types of 
medicines are best for people who are allergic to various types of drugs.Herbal 
medicines are also effective in boosting the mental health.Most of the ailments related 
to blood circulation like high blood pressure, varicose ulcers, and many others can be 
controlled through herbal medicine.Some herbal medicines are very good in reducing 
the cholesterol level in the blood stream. They are also used to treat coronary artery 
diseases.Herbal medicine can be used to reduce weight by regulating appétit. 
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2. REVIEW OF LITERATURE 
 Ososki et al., 2002 Reported Ethnobotanical literature survey of medicinal 
plants in the Dominican republic used for women’s health condition on the usage of 
Berberis aristata decotion For uro-genital problems can use as decotion preparation 
of seeds taken orally or wash bath. The field work in the Dominican republic revealed 
that herbs were used to treat many women’s health condition including uterine 
fibrosis, excessive uterine bleeding,endometriosis and hot flushes in menopause. 
 Dasgupta et al., 2013 investigated and reported b about the important 
phytochemicals present in the leaf extract. The preliminary screening showed the 
presence of many phytochemicals such as alkaloids,flavonoids, terpenoids, saponoin, 
fixed oils and fats. High Performance Thin Layer Chromatography analysis was 
carried out with optimized solvent system consisting of ethyl acetate, formic acid, 
glacial acetic acid and water in the ratio of 8:1:1:2. The densitometric scanning of the 
chormatograms of hydroaclcoholic extract showed 7peaks at 254 nm 8 peaks at 366 
nm. The phytochemicals detected in the present study justify the therapeutic uses of 
the leaves in the traditional medicines.  
 Isaac et al., 2007 conducted histopathological and biochemical studies on 
Short-term administration of an aqueous extract of Berberis aristata Integra var. 
crenata (Andr.)  in a 14-day sub-acute toxicity studies using female Sprague-Dawley 
rats on Berberis aristata Intergra (Ki) leaf extract for the treatment of ulcers, pain and 
adenoma of the prostate gland repoted about its traditionally use for orally 
administered multipurpose in Ghana and other parts of the world. 
Cruz et al., 2012 evaluated and studied on the topic Phytomedicine: 
International Journal of Phytotherapy & Phytopharmacology about Aqueous extract 
of Berberis aristata Pinnata (Kp) have been found effective in models to reduce acute 
anaphylactic reactions.They investigated on the effect of Kp and the flavonoid 
quercetin (QE) and quercitrin (QI) on mast cell activation in vitro and in a model of 
allergic airway disease in vivo. Treatment with Kp and QE in vitro inhibited 
degranulation and cytokine production of bone marrow-derived mast cells following 
IgE/FcɛRI crosslinking, whereas treatment with QI had no effect. Similarly, in 
vivo treatment with Kp and QE decreased development of airway 
hyperresponsiveness, airway inflammation, goblet cell metaplasia and production of 
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IL-5, IL-13 and TNF. In contrast, treatment with QI had no effect on these 
parameters. These findings demonstrate that treatment with Kp or QE is effective in 
treatment of allergic airway disease, providing new insights to the immunomodulatory 
functions of this plant. Berberis aristata Pinnata inhibits mast cell activation and 
prevents allergic airway disease. 
 Shazid et al., 2012 reported on the elucidated structure under the title 
Chemical and biological studies of Berberis aristata Pinnata (Lam.) growing in 
Bangladesh. In this study they  isolated compounds from K. Pinnata and elucidated 
their structures and to explore preliminary antioxidant, antimicrobial, cytotoxic and 
thombolytic activities of extractives of  the plant. The methanol extract of whole plant 
of K. Pinnata has been subjected to different chromatographic separation and 
purification processes to isolate the secondary metabolites. The structures of the 
isolated compounds have been elucidated by extensive NMR studies. 
 Patil et al., 2013 reported under Antidiabetic activity of Berberis aristata 
Pinnata in streptozotocin-induced diabetic rats by glucose independent insulin 
secretagogue action about the anti diabetic action of K.Pinnata in wich it was reported 
that it reduces fasting blood glucose level  
 Gad et al., 200633 studied on Biochemical study of the anti-diabetic action of 
the Egyptian plants fenugreek and balanites. It proceeded by evaluating the effects of 
21 days oral administration of Fenugreek seed and Balanites fruit extracts (1.5 g/kg 
bw) on the liver and kidney glycogen content and on some key liver enzymes of 
carbohydrate metabolism in STZ-diabetic rats were studied. In addition, the effects of 
these two plant extracts on the intestinal alpha-amylase activity in vitro and starch 
digestion and absorption in vivo were also examined. . 
 Patil et al., 2013 reported on hypoglycemic activity on Berberis aristata 
Pinnata Lam. (Crassulaceae) under the title Antidiabetic activity of Berberis aristata 
Pinnata in streptozotocin-induced diabetic rats by glucose independent insulin 
secretagogue action. The probable mechanism for insulin secretagogue action was 
evaluated through studies using diazoxide and nifedipine. The bioactive component 
from DCM fraction was studied using HPTLC, GCMS and IR.  
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 Dzhafarova et al., 2009 reported on Antidiabetic action of extract of Juglans 
Regia L study is on the impact of Iuglans Regia L on the pathological processes in 
alloxan-indeced dibatic animals. The investigation showed that extract from wall nuts 
leaves decreases the blood sugar level, has a positive impact on lipid metabolism. 
Antioxidant properties of an extract from leaves of the walnut tree (Juglans regia) are 
reported. 
 Radhika et al., 201136 Did a major evaluation on Antidiabetic and 
Hypolipidemic Activity of Punica Granatum Linn on Alloxan Induced Rats the study 
aimed to evaluate the antidiabetic and hypoglycemic activity of Punica granatum. 
Diabetes & hyperlipidemia was induced by the intra peritoneal injection of alloxan 
mono hydrate (120mg/kg) for 2 consecutive days. Diabetes was confirmed 2days after 
the last alloxan dose administration by determining the blood glucose concentration. 
Treatments were started after confirmation of diabetes in rats.During diabetes, the 
excess glucose present in the blood reacts with hemoglobin to form glycosylated 
hemoglobin. So the total hemoglobin level is lowered in alloxan induced diabetic rats. 
Alloxan induced diabeteshas been observed to cause a massive reduction of the beta 
cells of the islets of pancreas leading to hyperglycemia. Rats treated with alloxan 
(120mg/kg), for 2 consecutive days, showed an increase in the concentration of 
glucose, triglycerides, cholesterol, LDL cholesterol, VLDL cholesterol and a decrease 
in the level of HDL cholesterol and hemoglobin content. Administration of crude 
powder of Punica granatum husk reduced the concentration of glucose, triglycerides, 
cholesterol, LDL cholesterol, VLDL cholesterol and raised the level of HDL 
cholesterol and hemoglobin content in the blood of both group-I normal and group III 
alloxan diabetic rats treated. 
 Saif-Ur-Rehman et al., 2011 presented the  work on Antidiabetic Effect of 
Aloe vera Extract on Alloxan Induced Diabetic Rats. It was carried out to investigate 
the antidiabetic effect of Aloe vera extract in normal and alloxan induced diabetic 
rats.  
 Kuroda et al., 2005  studied on the turmeric (Curcuma Longa L. rhizomes) 
EtOH extract the Hypoglycemic effects of turmeric (Curcuma Longa L. rhizomes) on 
genetically diabetic KK-Ay mice it shows significant suppression and an increase in 
blood glucose level in type 2 diabetic KK-A(y) mice. 
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 Mondal et al., 2008 did a preliminary and antidiabetic screening on the title 
 Antidiabetic activity of Diospyros Malabarica Kostel bark: a preliminary 
investigation for possible mode of action. The extract exerted significant 
antihyperglycemic effect in alloxan-induced hyperglycemia and resulted in increase in 
plasma protein content and decrease in alkaline phosphatase, cholesterol and 
triglyceride levels when compared with those in the diabetic control group. However 
there were no significant changes in body and kidney weights of the DM extract-
treated animals, compared to those of the untreated diabetic rats as a control.  
 Grover et al., 200240 conducted a research of Medicinal plants of India with 
anti-diabetic potential on the plants mentioned in ancient literature or used 
traditionally for diabetes have shown anti-diabetic property. The present paper 
reviews 45 such plants and their products (active, natural principles and crude 
extracts) that have been mentioned/used in the Indian traditional system of medicine 
and have shown experimental or clinical anti-diabetic activity. 
 Rajnish Gupta et al., 2011 reported on Antidiabetic efficacy of  Mangifera 
Indica seed kernels in rats. The study was conducted to examine the hypoglycemic 
potency of seed kernels of Mangiferaindica ethanol extract (MIEtE) in 
streptozotocindiabetic rats. Remarkable abnormalities were observed in serum and 
tissue parameters in hyperglycemic rats after streptozotocin administration 
 Sabjan Khaleel Basha and Vinoji Sugantha Kumari.2012 reported on In 
vitro antidiabetic activity of Psidium Guajava seeds extracts. In this they did the 
evaluation of the glucose uptake of (antidiabetic activity) crude n-hexane, ethanol, 
ethanol and aqueous leaf extracts of P.guajava. Methods: P.guajava leaf extracts were 
subjected to inhibitory effect of glucose utilization using specific standard in vitro 
procedure. 
 Yoshino  et al., 2009 reported on the title Anti-diabetic activity of a leaf 
extract prepared from Salacia Reticulata in mice The effects of a water extract 
prepared from the leaves of Salacia reticulata on the absorption of sugars in normal 
and type 1 diabetic mice were investigated.  
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 Akhani et al., 2004 reported on antidiabetic study of  Zingiber officinale 
Roscoe as Anti-diabetic activity of Zingiber Officinale in streptozotocin-induced type 
I diabetic rats The fresh and dried rhizome of Zingiber officinale Roscoe (commonly 
known as ginger) is widely used in traditional medicine.The study is on the effect of 
the juice of Z. officinale (4 mL kg(-1), p.o. daily) for 6 weeks on streptozotocin 
(STZ)-induced type I diabetic rats with particular reference to the involvement of 
serotonin (5-hydroxytryptamine; 5-HT) receptors in glycaemic control. 
  Ramadan et al., 2013 observed two parameters on the diabetic induced rat on 
title Hypoglycemic and hepatoprotective activity of Rosmarinus Officinalis extract in 
diabetic rats The present study examined the effect of water extract (200 mg/kg body 
weight) of Rosmarinus officinalis L. in streptozotocin (STZ)-induced diabetic rats for 
21 days. The hepatoprotective effects were investigated in the liver tissues. 
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3. PLANT PROFILE 
 
 
 
 
 
 
 
Berberis aristata Leaves 
 
 
 
 
 
 
Plant Profile 
Kingdom  Plantae 
Order  Ranunculales 
Family  Berberidaceae 
Genus  Berberis 
Species  B. aristata 
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Berberis aristata 
Herbalism or "herbal medicines” have a long history to cure several kinds of 
human diseases from the various parts of the plants such as leaf, stem, bark, leaves , 
etc. [2] Plants have been the basis for medical treatments through much of human 
history, and such traditional medicine is still widely practiced today. Modern 
medicine recognizes herbalism as a form of alternative medicine, as the practice of 
herbalism is not strictly based on evidence gathered using the scientific method. Many 
of the pharmaceuticals currently available to physicians have a long history of use as 
herbal remedies, including opium, aspirin, digitalis, and quinine. The World Health 
Organization (WHO) estimates that 80 percent of the population of some Asian and 
African countries presently uses herbal medicines for some aspect of primary health 
care. The use of, and search for, drugs and dietary supplements derived from plants 
have accelerated in recent years. Pharmacologists, microbiologists, botanists, and 
natural-products chemists are combining the Earth for phytochemicals and leads that 
could be developed for treatment of various diseases. Among the 120 active 
compounds currently isolated from the higher plants and widely used in modern 
medicine today, 80 percent show a positive correlation between their modern 
therapeutic use and the traditional use of the plants from which they are derived. More 
than two thirds of the world's plant species at least 35,000 of which are estimated to 
have medicinal value come from the developing countries [1] . The plant is an erect 
glabrous spinescent shrub, 3-6 m in height with obovate to elliptic, subacute to obtuse, 
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entire or toothed leave (3.8-10 × 1.5-3.3 cm long), flowers are yellow in corymbose 
racemes, petiole distinct up to 4 mm, inflorescence a single drooping raceme (2.5-7.5 
cm long), and dense-flowered. Pedicles are stout, 4-6 mm long, fruits are 7-10 mm 
long, ovoid, bluish black or bright red in color and covered with a thick pale or bluish 
white bloom and are born in pendulous clusters. Berberis aristata belongs to the 
family Berberidaceae, is an important medicinal plant. It is also called as 
‘daruharidra’, found in the Himalayas and other parts of the world. A very valuable 
ayurvedic preparation ‘Rashut’ is prepared by this plant and are used for the curing of 
diseases such as, jaundice ophthalmic and skin diseases. Berberis aristata is 
characterized by an erect spiny shrub, ranging between 2 to 3 m (6.6 to 9.8 ft) in 
height. It is a woody plant, with bark that appears yellow to brown from the outside 
and deep yellow from the inside. The bark is covered with three-branched thorns, 
which are modified leaves, and can be removed by hand in longitudinal strips. The 
leaves are arranged in tufts of five to eight and are approximately 4.9 cm (1.9 in) long 
and 1.8 cm (0.71 in) broad. The leaves are deep green on the dorsal surface and light 
green on the ventral surface. The leaves are simple with pinnate venation. The leaves 
are leathery in texture and are toothed, with several to many small indentations along 
the margin of the leaf. Daruharidra has been observed to be diaphoretic, rejuvenating, 
antipyretic properties and as Raja Nighantu (bitter tonic). The plant is native to 
Himalayas at an elevation 2000 to 3500 metres and predominantly found in the Nilgiri 
mountain range in Southern India. The shrub grows upto 1.5 – 2.0 metres in height, 
with a thick woody leaves covered with a thin brittle bark. The leaves are cylindrical, 
straight, tapering, very sharp, hard, smooth spine with yellow, numerous, stalked, 
arranged in drooping racemic flowers and small berry, ovoid and smooth fruits. The 
flowering season of this plant is observed from April to May. Some of the major 
Daruharidra formulations are Darvyadi kavatha, Darvyadi leha, Darvyadi taila, 
Rasanjana and Dasanga lepa. Due to several clinical important formulations, 
Daruharidra is of trade importance (high volume/high value) and is of conservation 
concern being an endemic species. Market survey in India indicates that Berberis 
asiatica, Berberis lycium, Cosinium fenestratumand Morinda umbellata are traded as 
substitutes of B. aristata.  
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4. AIM AND OBJECTIVE 
 The Diabetes Mellitus is worldwide problem due to the lifestyle changes lead 
to decreased physical activity, increased consumption of fat, sugar and calories, and 
higher stress levels, affecting insulin sensitivity and obesity. Based on the above 
causative factor to increased tenfold, from 1.2% to 12.1%, between 1971 and 2000 
entire world. It estimates is estimated that 61.3 million people aged 20-79 years live 
with diabetes in India (2011). This number is expected to increase to 101.2 million by 
2030
. 
There are many synthetic drugs used for the treatment of diabetes such as 
Glibenclamide-sulphonylureas were used in India as combination therapy because of 
its more side effects were reported. Several literatures indicated that the herbal drugs 
are less adverse effect when compared with synthetic drugs. Berberis aristata one of 
most traditionally using hypoglycemic drug among tribes in Africa and its same 
species K.Pinnata was scientifically reported but Berberis aristata is not scientifically 
validated.  Based on the above mentioned reasons, one new research is required to 
develop one new drug with activity and less side effects, which will be work 
multifactorial anti diabetic mechanism. Allopathic medicines are very costly In 
contrast, herbal medicines are very cheap. This cost effectiveness makes them all the 
more alluring. The work provides scientific validation for the use of leaf against 
diabetes by revealing the chemical compounds may be present in the plant. The 
prediction of biological activity of the chemical compounds present in the extract 
wills also supports the invitro results after its phytochemical analysis. Herbal drugs 
were expelled milde side effects reported in literatues. The present study is attempt to 
develop a novel plant based antidiabetic drug, which will be evaluated by using 
Invitro and Invivo methods. 
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5. PLAN OF WORK 
1. Collection and authentification of the genuine plant material. 
2. Shade drying and granulation of the dried leaves. 
3. Sequential extraction of the plant material using petroleum ether, ethyl 
acetate and ethanol. 
4. Invitro antidiabetic study using α-amylase inhibition assay. 
5. Selection of active extract with higher activity. 
6. Phytochemical analysis of active extract. 
7. Acute toxicity study. 
8. Invivo antidiabetic study of active extract. 
I) Normal animal 
a) OGTT 
b) Hypoglycemic 
II) Streptazocin induced diabetes mellitus 
      a) Multiple dose study 
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6. MATERIALS AND METHODS 
a)Plant collection and authentification 
The leaves s of Berberis aristata were collected from Nilgiri hills Gudalur, 
Kerala and which was authenticated by Dr.Raghu.A.V Scientist-B,Extension & 
Training, Kerala Forest Research institute Peechi – 680 653, Thrissur.  
b)Preparation of  coarse powder and Extraction technique 
The leaves were shade dried at room temperature for 10 days. Then these were 
milled into powder by mechanical grinder. This powder was sequentially extracted to 
their increasing polarity with Petroleum ether, Ethyl acetate, Ethanol respectively. 
About 500gm of powdered leaves  was uniformly packed into a thimble in a soxhlet 
apparatus and extracted with 1000ml Petroleum ether, Ethyl acetate and Ethanol, 
respectively. Constant heat was provided by Mantox heater for recycling of the 
solvent. The process of extraction continues for 1-2 hours for each solvent. The 
excess solvent was evaporated and the dried extracts were kept in refrigerator at 4ºC 
for their future use in phytochemical analysis and pharmacological screenings. 
c)Invitro antidiabetic activity  of Berberis aristata leaves  extracts 
Alpha-amylase inhibition assay 
Chemicals or reagents 
Potato starch, trichloroacetic acid, Folin-Ciocalteau reagents were purchased 
from SD Fine Pvt. Ltd., Mumbai, 3,5-dinitrosalicylic acid, Tris buffer, linoleic acid, 
ammonium molybdate, were purchased from Hi-Media Pvt. Ltd., Mumbai, α-amylase, 
α-glucosidase enzymes, xanthine oxidase, quercetin, hypoxanthine, pyrocatechol were 
purchased from SRL Pvt. Ltd., Mumbai. Glucose assay kit from Agappe diagnostic 
Pvt. Ltd., Kerala, Acarbose was obtained from Bicon Pvt. Ltd., Chennai, ferrozine, 
(2'2-azobis (2-amidino propane) dihydrochloride), butylated hydroxy toluene from 
Loba Cheme. All other chemicals used in the study were obtained commercially and 
were of analytical grade. 
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Instrument used 
UV-visible Spectrometer (Systronic double beam- UV-2201). 
Preparation of extract 
Leaves extraction used in invitro and invivo studies were prepared by using 
suitable solvents (Carboxy methyl cellulose). 
Experimental procedure for α-amylase inhibition assay 
A total of 500 µl of test samples and standard drug (100-1000µg/ml)  were 
added  to  500  µl  of  0.20  mM  phosphate  buffer  (pH  6.9)  containing  α-amylase 
(0.5mg/ml) solution and were incubated at 25°C for 10 min. After these, 500 µl of 
a 1% starch solution in 0.02 M sodium phosphate buffer (pH 6.9) was added to 
each tube. The reaction mixtures were then incubated at 25°C for 10 min. The 
reaction was stopped with 1.0 ml of 3, 5 dinitro salicylic acid colour reagent. The 
test tubes were then incubated in a boiling water bath for 5 min, cooled to room 
temperature. The reaction mixture was then diluted after adding 10 ml distilled 
water and absorbance was measured  at  540  nm.  Control  represent  100%  
enzyme  activity  and  were conducted in similar way by replacing extract with 
vehicle. 
Calculation of 50% inhibitory concentration (IC50) 
The concentration of the plant extracts required to scavenge 50% of the 
radicals (IC50) was calculated by using the percentage scavenging activities at five 
different concentrations of the extract. Percentage inhibition (I %) was calculated by 
(Ac-As) 
I %  =       ---------------  x 100 
Ac 
 
Where, 
Ac      =  Absorbance of the control 
As      =  Absorbance of the sample. 
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d) Thin layer chromatographic profiling 
Practical requirements 
 Stationary phases 
 Glass plates 
 Mobile phase 
 Preparation and activation of TLC plates 
 Application of sample  
 Development tank  
 Development technique 
 Detecting or visualizing agents 
 
Glass plates 
  Specific dimensions like 20 cm*20cm (full plate), 20cm*10cm (half plate), 
20 cm*5cm (quarter plate) can be used. It should be good quality and can withstand 
temperature used for drying. 
Preparation and activation of TLC plates   
 Mixture of stationary phase and water forms slurry. TLC plates prepared by 
pouring, dipping , spraying or spreading. In pouring technique, slurry prepared and 
poured on the glass plate. Slurry spread uniformly on glass plate. Plates are dried in 
oven. In dipping technique two plates dipped in slurry, separated and dried. 
Disadvantage is that large quantity slurry required. 
Spreading technique   
 In this technique TLC spreader is used. The glass plates are stacked on base 
plate. Slurry poured in the reservoir of TLC spreader. Thickness adjusted using knob 
in the spreader. 0.25 mm is normally used thickness for analytical purposes. Spreader 
rolled on the plates and air drying the plates. Plates are activated by keeping at 100 
degree Celsius to 120 degree Celsius for one hour. Activated plates can be stored in 
thermostatically controlled oven for further use.  
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Application of sample 
  The concentration of sample of standard should be minimum for good spots. 
2- 5ug of 1% solution of standard or sample spotted using capillary tubes. Spots 
should be 2 cm above the base of plate and spotting area should not be immersed in 
mobile phase. At least 4 spots can be spotted on quarter plate.  
Development tank  
The developing tanks require more solvent for developing tank –having hump 
in the middle and require less solvent. It should be lined inside with filter paper 
moistened with mobile phase 
Mobile phase   
The solvent or mobile phase depends on various factors. 
Nature of substance 
Nature of stationary phase 
Mode of chromatography 
Separation to be achieved. Analytical or preparative 
 
Procedure 
 Commercial sheet pre coated with silica gel are available. Select a solvent by 
testing out the samples in various solvents. Dissolve a small quantity of ethanolic 
extract of Berberis aristata leaves of the unknown in different flask containing 
solvents of different polarity. Place the TLC plates, the spotted side down in to the 
chamber so that the lower the pencil line about the solvents. Remove the plate from 
the development chamber and allowed to dry. Plate is placed under UV light, dark 
spots are observed. 
Quantitative analysis 
                  Rf =      Distance moved by solute                               
                              Distance moved by solvent 
                 
                  Rf = retardation factor  
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e) Preliminary phytochemical screening of ethanolic leaves extract of Berberis 
Aristata 
  The ethanolic leaves extract of Berberis aristata was used for testing 
preliminary phytochemical screening in order to detect major chemical groups. 
Test for carbohydrates 
 Molisch’s test: Dissolved small quantity of 300mg alcoholic and dried leaves  
extract powder of Pimenta dioica separately in 4ml distilled water and filtered. 
The filtrate was subjected to Molisch’s test.  
 Fehling’s test: Dissolve a small portion of extract in water and treat with 
Fehling’s solution. 
 Phenols test: The extract was spotted on a filter paper. A drop of 
phosphomolybdic acid reagent was added to the spot and was exposed to 
ammonia vapours. 
Test for flavanoids  
 Shinoda test: To 2 to 3ml of extract, a piece of magnesium ribbon and 1ml of 
concentrated HCl was added. 
 Lead acetate test: To 5ml of extract 1ml of lead acetate solution was added.  
Test for tannins 
 Braemer’s test: To a 2 to 3ml of extract, 10% alcoholic ferric chloride solution 
was added. 
Test for steroid/terpenoid 
 Liebermann-Burchardt test: To 1ml of extract, 1ml of chloroform, 2 to3ml of 
acetic anhydride and 1 to 2 drops of concentrated Sulphuric acid are added. 
Test for alkaloids 
 Draggendorf’s test: A drop of extract was spotted on a small piece of 
precoated TLC plate and the plate was sprayed with modified Draggendorf’s 
reagent.  
 Hager’s test: The extract was treated with few ml of Hager’s reagen. 
 Wagner’s test: The extract was treated with few ml of Wagner’s reagent. 
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Tests for Glycosides 
 Legal’s test: Dissolved the extract [0.1g] in pyridine [2ml], added sodium 
nitroprusside solution [2ml] and made alkaline with Sodium hydroxide 
solution. 
Test for Saponins 
 Foam test: 1ml of extract was dilute with 20ml of distilled water and shaken 
with a graduated cylinder for 15 minutes. 
Test for Anthraquinones 
 Borntrager’s test: About 50 mg of powdered extract was heated with 10% 
ferric chloride solution and 1ml of concentrated HCl. The extract was cooled, 
filtered and the filtrate was shaken with diethyl ether. The ether extract was 
further extracted with strong ammonia. 
Test for Amino acids 
 Ninhydrin test: Dissolved a small quantity of the extract in few ml of water 
and added 1ml of ninhydrin reagent. 
Test for fixed oils and fats 
  Press small quantity of the petroleum ether extract between two filter paper. 
Note: the results for the above experiments can be noted as follows. 
 If the response to the test is high it can be noted as +++ which indicates that 
the particular group is present as the major class. 
 If the response is average then note it as ++ indicates the presence in moderate 
quantity. 
 If the response is very small then note it as + indicating the presence of only in 
traces. 
 If no response is then negative. 
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g) Acute toxicity study 
 In a research study when a drug is administered to a biological system there 
will be some interactions may happen .In most case these are desired and usefull,but 
many effects are not advantageous. Acute, subacute and chronic toxicity studies are 
performed by the manufacturers in the investigation of a new drug.Acute toxicity is 
involved in estimation of LD50 (It is the lethal dose (cuasing death)to 50% of tested 
group animals)54. 
LD50 (median lethal oral dose) 
LD 50 (median lethal oral dose) is a statistically derived oral dose of a 
substance that can be expected to cause death in percent of animals when 
administered by the oral route. The LD50 value is expressed in terms of weight of test 
substance per unit weight of animal (mg/kg) 
  In this study acute toxicity study was carried out in wistar albino rats. The 
procedure was followed by using OECD 423(Acute toxic class method).The rats are 
fasted overnight, prior to dosing. The three dose levels are administered by the help of 
oral feeding needle over the prior of 24 hours. After the drug has been administered, 
food may be with held for a further 3-4 hours in rats. The purpose of sighting study is 
to allow selection of the appropriate starting dose for main study. The test substance is 
administered to a single animal in a sequential manner following from the fixed dose 
levels of 5, 50, 300 and 2000mg/kg. The interval between dosing of each level is 
determined by the mortality/onset, duration and severity of toxic signs over the period 
of 24 hours, special attention given during the first 4 hours. Four hours after the drug 
administration, provide the food and water for 14 days and daily observed some 
parameters such as food intake, water intake, mortality, onset, Duration and severity 
of toxic signs. The animal weight is recorded on weekly once. On the day fourteen all 
the animals are sacrificed, to isolate the organs and observe the histopathological 
changes. Based on the mortality result of sighting is decided and carried out with five 
animals per dose level (5 or 50 or 300 or 2000mg/kg).Based on the mortality result on 
14th day of observation, the doses for in vivo study are selected.  
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h) Invivo antidiabetic activity of Berberis aristata leaves extract in 
streptozotocin induced diabetic wistar albino rats. 
Wistar albino rats (150- 200 grams) of both sexes were procured from Dr. 
Samsun laboratories, Tirupur-TN, India.  Prior to the experiment the rats 
were housed in a clean polypropylene cages (6 rats/ cages) for a period of 7 
days under standard temperature (25 - 30o  c) , relative humidity (45 – 55%), 
dark / light cycle (12 /12 hrs). The studies were performed with the approval 
of Organisational Animal Ethics Committee (OAEC) (DAEC/TNA/965/345/16).  
The animals were put in overnight fasting were deprived of food for 16 hrs but 
allowed free access of water. 
Chemicals: 
 Streptozotocin from   Loba Chemie. Standard Glibenclamide (Daonil) from 
Aventis Pharma. Ethanol (Analytical grade) and 5% Dextrose solution Glucose 
Estimation Kit from  Gluco Dr Super sensor 
Hypoglycemic Test 
Groupings were done as follows: Group I served as control – Carboxy Methyl 
Cellulose (CMC) 0.5% (0.3ml\100g rat), Group II served as Positive control – 
Glibenclamide (2mg /kg), Group III served as  aqueous ethanolic extract of Berberis 
aristata– (200mg/kg), Group IV served as  aqueous ethanolic extract of Berberis 
aristata– (400mg/kg). Blood samples were collected by the tail nipping method and 
glucose level checked by glucometer.  After  drug Administration blood samples have 
been collected different time intervals at 30, 60 and 120. 
Oral Glucose Tolerance Test 
Groupings were done as follows: Group I served as control – Carboxy Methyl 
Cellulose (CMC) 0.5% (0.3ml\100g rat), Group II served as Positive control – 
Glibenclamide (2 mg /kg), Group III served as  aqueous ethanolic extract of Berberis 
Aristata– (200mg/kg), Group IV served as  aqueous ethanolic extract of Berberis 
aristata– (400mg/kg). All the groups of animals were fasted for 24h and blood 
samples were collected before drug or solvent treatment. The drug, extract and 
solvent, have been adminisratered to different groups and  30mins later all the groups 
of rats were treated  with glucose orally at dose 10gm/kg body weight by using oral 
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feeding needle.  Blood samples were collected by the tail nipping method and glucose 
level checked by glucometer.  After drug Administration blood samples have been 
collected different time intervals at 30, 60 and 120. 
Induction of diabetes to animals 
A single dose (100 mg/kg b.w., i.p.)  of streptozotocin monohydrate  
dissolved in sodium citrate buffer was used for the induction of diabetes in 
rats after overnight fasting. After 1 hr of streptozotocin monohydrate 
administration, the animals were given feed and libitum  and  5%  dextrose  
solution  was  also  given  in  feeding  bottle  for  a  day  to overcome early 
hypoglycaemic  phase. The animals were stabilized for a week and animals 
showing blood glucose level more than 200 mg/dl were selected for the study. 
Experimental design 
Five  groups  of  rats  six  in  each  groups  received  the  following  
treatment schedule for 14 days. 
GROUP I        -          Normal control (normal saline 10 ml /kg, P.O) 
        GROUP II      -          Streptozotocin treated control (100 mg/kg, I.P)  
        GROUP III     -          Streptozotocin (100 mg/kg, I.P) + 
  Standard drug Glibenclamide (2 mg/kg, P.O). 
GROUP IV      -       Streptozotocin (100 mg/kg, i.p.) + EEBAL.(200 mg/kg, 
P.O)  
GROUP V       -      Streptozotocin (100 mg/kg, i.p.)+ EEBAL. (400 mg/kg, 
P.O) 
 Plant leaves extract, standard drug and normal saline were administered with 
the help of oral feeding needle. Group I serve as normal control which received 
normal saline for 14 days. Group II to Group V were diabetic control rats. 
Group IV and Group  V (which  previously  received  streptozotocin100mg/kg)  
were given  fixed  doses  of ethanol leaves extract (200 mg/kg, P.O, 400 mg/kg, 
P.O) of Berberis aristataand group III received standard drug Glibenclamide (2 
mg/kg,P.O) for 14 consecutive days. (EEBAL- Ethanolic extract of Berberis 
aristata Leaves). 
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Collection of blood samples 
 Fasting blood samples were drawn from retro orbital puncture of rats at 
weekly intervals till the end of the study 1, 7, and 14 days. 
Estimation of biochemical parameters Serum blood glucose 
 On  1,  7,  and  14  days  fasting  blood  samples  were  collected and analyzed 
the blood glucose. 
Blood glucose level 
 The blood glucose level test measures the amount of glucose in the blood 
sample obtained from the animals. The test is usually performed to check for 
elevated blood glucose levels which can be an indication of diabetes or insulin 
inhibition. 
Statistical analysis 
 Statistical analysis was done by using GRAPHPAD PRISM 5.0.All the 
values of Biochemical parameters and body weight were expressed as Mean ± 
Standard Error Mean (SEM). The values were analyzed for statistical significance 
using one- way analysis of variance (ANOVA), comparison was done by using 
Dunnett’s t test. P values < 0.05 were considered as significant, P values < 0.01 
were considered as very significant, P values < 0.001 were considered as highly 
significant and ns were considered as not significant.  
 
 
 
 
 
 
 
 
  
Department of Pharmacology                    29                  J.K.K. Nattraja College Of Pharmacy    
 
7. RESULTS  
a)Appearance and percentage yield of EEHC (Ethanolic Extract of Berberis 
aristata Leaves) 
  EEBAL was a semisolid brownish colour extract and the percentage yield was 
found to be 14.35% 
b) invitro antidiabetic study     
Table No:1, α-Amylase Inhibition of Petroleum Ether extract of   Berberis 
aristata leaves 
Concentration(µg/ml) Percentage Inhibition (%) 
0 0 
25 29 
50 33 
75 42 
100 53 
125 56 
 
 
Fig No :3α-Amylase Inhibition of Petroleum Ether extract of   Berberis aristata leaves  
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Table no:2, α-Amylase Inhibition of  Ethyl acetate Extract of Berberis aristata 
leaves 
Concentration(µg/ml) Percentage Inhibition(%) 
0 0 
25 34 
50 41 
75 48 
100 56 
125 60 
 
 
Fig No:4 α-Amylase Inhibition of  Ethyl acetate Extract of Berberis aristata 
leaves 
 
 
 
 
 
 
 
 
  
Department of Pharmacology                    31                  J.K.K. Nattraja College Of Pharmacy    
 
 
Table no:3, α-Amylase Inhibition of  Ethanolic Extract of Berberis aristata 
leaves 
Concentration(µg/ml) Percentage Inhibition(%) 
0 0 
25 30 
50 36 
75 50 
100 56 
125 61 
 
 
 
Fig No:5
 α-Amylase Inhibition of  Ethanolic Extract of Berberis aristata leaves 
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Table no:) 4, α-Amylase Inhibition  of Acarbose  (Positive control 
Concentration(µg/ml) Percentage Inhibition(%) 
0 0 
25 25 
50 45 
75 53 
100 56 
125 65 
 
 
Fig No:6 α-Amylase Inhibition  of Acarbose  (Positive control 
 
Result 
 %Inhibition of Petrolium ether extract of Berberis aristata leaves = 91 µg/ml      
%Inhibition of Ethyl acetate extract of Berberis aristata leaves     =  80 µg/ml        
%Inhibition of Ethanolic extract of Berberis aristata leaves           =  75 µg/ml          
%Inhibition of Acarbose (Positive control)                          =  61 µg/ml      
 Minimum % Inhibition   was found in Ethanolic extract of Berberis aristata 
leaves which resemblance to %Inhibition of positive control, So Ethanolic extract 
of Berberis aristata contain active constituents of antidiabetic. 
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c) TLC study  
           Table No: 5, Results of ethanolic extract of Berberis aristata leaves 
Si 
No. 
Solvents Concentration Rf  value 
1. 
 
Toluene + Ethyl acetate 7:3 0.62 
2. Toluene + Ethyl acetate + Glacial 
acetic acid 
5:5:1 0.76 
3. Petrolium ether+Chloroform 7:3 0.56 
4. Ethyl acetate + Methanol 
 
1:1 0.88 
5. Hexane+Dichloro methane 1:1 0.67 
6. Ethyl acetate + Methanol 3:1 0.59 
7. Dichloro methane +Hexane 3:1 0.72 
 
Rf Value range high-Polar substances present. 
Rf value range low-Low polar substance present. 
Solubility of compounds depend upon the polarity of solvents. 
Obtained Rf values were confirmed by standard Rf values. 
 Rf values obtained for my extract ranges from 0.56 to 0.88,So my extract may contain 
compounds like Flavanoids,Glycosides and Alkaloids. 
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d) Phytochemical studies 
Table No : 6, Results of ethanolic extract of Berberis aristata leaves 
 
Class of  
compounds 
 
Tests performed 
 
Results  
 
 
Carbohydrates 
 
Molisch’s test 
Fehling’s test 
 
 
- 
 
Phenols 
 
Phosphomolybdic acid test 
 
+ 
 
Flavonoids 
 
Shinoda test 
Lead acetate test 
 
 
+ 
+ 
 
Tannins 
 
Braemer’s test 
 
_ 
 
Alkaloids 
Wagner’s 
Mayer’s 
Draggendrof’s test 
+ 
+ 
+ 
 
Glycosides 
Legal’s test 
Brontranger’s test 
+ 
+ 
+ 
 
Saponins 
 
Foam test 
 
+ 
 
Sterols 
 
Salkowski’s test 
 
_ 
 
Amino acids 
 
Ninhydrin test 
 
_ 
 
Terpenoids 
 
Lieberman Burchardt test 
 
+ 
 
+Present in moderate amount 
-Absence 
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 The phytochemical studies results revealed that the Molisch’s test no 
characteristic observation indicated the absence of carbohydrates, by 
phosphomolybdic acid test Blue coloration of the spot indicated the presence of 
phenols. Shinoda test and Lead acetate test gave pink or red coloration of the solution 
indicated the presence of flavonoids Flocculent white precipitate also indicated the 
same. There is no dark blue or greenish grey coloration of the solution indicated the 
absence of of tannins in the drug. No characteristic observation for steroids and dark 
pink or red coloration of the solution indicated the presence of terpenoids. Orange 
coloration of the spot indicated the presence of alkaloids. Yellow or reddish brown 
precipitation precipitation indicated the presence of alkaloids. Pink to red colour 
solution indicates the presence of glycosides. No layer of foam formation indicates 
the absence of Saponins. If the response to the test is indicated table-1high it can be 
noted  or  which indicates that the particular group is present as the major class. If the 
response is average then note it as indicates the presence in moderate quantity and 
note it as indicating the presence of only in traces. If no response is then negative.   
                          TABLE-I, Hypoglycemic Test     
TREATMENT 
DOSE 
mg/kg 
BLOOD GLUCOSE LEVEL (mg/dl) 
0 min 0.5hr 1 hr 
CONTROL 
CARBOXYME
THYL 
CELLULOSE(
CMC) 
0.5 % 68.00±2.429 68.17±2.587 71.83±2.372 
POSITIVE 
CONTROL 
Glibenclamide 
2 69.00±0.6325 52.83±4.037** 32.83±1.515*** 
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The glucose levels were analyzed by using glucometer and each value 
is the mean ± standard error (n= each group consist of 6 
animals)(p<0.05)*, (p<0.001)**& (p<0.0001)*** as compared to 
control & positive control group evaluated by one  way, ANOVA 
followed by Dunnet ‘t’ test. 
 
 
 
 
AQUEOUS 
ETHANOLIC 
EXTRACT OF 
BERBERIS 
ARISTATA 
200 68.80±2.245 60.17±3.497* 59.33±3.584* 
AQUEOUS 
ETHANOLIC 
EXTRACT OF 
BERBERIS 
ARISTATA 
400 68.00±2.429 53.00±2.309** 34.17±1.138*** 
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The hypoglycemic test results have shown Table No:I, which indicated  aqueous 
ethanolic extract of Berberis aristatatreated animals 200 & 400,  significantly 
decreased in blood glucose level (0.84± 1093↓ & 18.83±3.879↓) (P<0.05)*, 
(P<0.001)**&  (P<0.0001)*** when compared to control and positive control 
 
  
Department of Pharmacology                    38                  J.K.K. Nattraja College Of Pharmacy    
 
g) Invivo antidiabetic study 
Table No: 13, Results of the effects of ethanolic extract on blood Glucose levels 
 
SL. 
No. 
 
 
TREATMENT 
 
Blood glucose level (mg/dl) day 
 Day    1         Day 7 Day 14 
1 Normal control 
10 ml/kg P.O 
79.83±2.833 75.7±4.014 76.7± 4.944 
2 Negative control 265.2±3.85 270.1±2.9 275.2±2.5 
3 Possitive control 
(Glibenclamide 
2mg/kg) P.O 
255.83±2.386 135.63±3.8*** 112±2.8*** 
4 EEBAL 200 mg/kg P.O  260±3.5 250.3±3.138** 245.2±3.250** 
5 EEBAL 400 mg/kg P.O 263±4.55 173.1±2.88*** 162.1±1.8*** 
EEHC-Ethanoloc extract of Berberis aristata Leaves 
(The values were expressed as Mean ± S.E.M. (n=6 animals in each group). 
The experimental results have indicated on Table No:13. The negative control 
group glucose levels were significantly increased when compared to each other 
groups. All the groups of animals were affected in diabetes, which indicated blood 
glucose levels were slight changes in the blood glucose level  ( 4.13±1.207↓& 
1.±0.93↑) for normal control group at 7th and 14th days . On day 7th glucose levels 
were significantly decreased glibenclamide 2mg/kg treated group (120.2±1.414↓& 
23±1↓) (P<0.05)*, (P<0.001)**&  (P<0.0001)*** when compared with control group 
at 7th and 14th days. The ethanolic leaves extract of Berberis aristatatreated groups 
200 & 400 mg/kg were dose dependent manner decreased (P<0.001)**&  
(P<0.0001)*** (10±0.362↓& 90±1.67↓) when compared  with control group but 
positive control have more anti diabetic activity  at 7th day.  The aqueous ethanolic 
leaves extract of Berberis aristata at the dose level 400mg/kg have equipotent activity 
(90±1.67↓&120.2±1.414↓when compared with positive control at 7th day. The 
ethanolic leaves extract of Berberis aristata 200 & 400 mg/kg have been expressed 
dose dependent anti diabetic action (P<0.001) **& (P<0.0001) *** when compared to 
control and positive control. On day 14th, ethanolic leaves extract of Berberis aristata 
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treated animals 200 & 400 mg/kg significantly decreased and maintain the blood 
glucose level (5.1±0.07↓ & 11±1.08↓), (P<0.001) **& (P<0.0001) *** when 
compared to control and positive control.  
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                                     Table-Ii, Oral Glucose Tolerance Test  
 
TREATME
NT 
DOSE 
mg/kg 
Blood Glucose Level (mg/dl) 
0 min 0.5hr 1 hr 1.5hr 2 hr 2.5hr 3hr 
Control 
Carboxymet
hyl 
Cellulose(C
mc) 
0.5 %  68.00±2.
429 
142.5±6.292 187.5±9.465 172.5±12.25 157.5±12.38 153.5±12.83 130.2±13.31 
Positive 
Control 
Glibenclami
de 
2 69.00±0.
6325 
104.2±7.323*
* 
110.5±6.980
*** 
93.67±1.308
*** 
83.67±1.308
*** 
77.17±4.070*
** 
74.33±2.940
*** 
Aqueous 
Ethanolic 
Extract Of 
Berberis 
Aristata 
200  68.80±2.
245 
128.3±6.009 147.3±2.404
* 
138.5±5.667
* 
128.5±5.667
* 
113.8±6.760*
* 
108.8±6.107
** 
Aqueous 
Methanolic 
Extract Of 
Berberis 
Aristata 
400 68.00±2.
429 
115.0±6.191*
* 
121.2±6.188
** 
103.3±4.766
***a 
93.33±4.766
*** a 
86.67±3.602*
**a 
83.67±2.906
***a 
The glucose levels were analyzed by using glucometer and all values are expressed as Mean±SEM (n=6), Group 2 was compared with group 1, Groups —
3,4 were compared with group 2; *p<0.05, **p<0.01,p<0.001*** evaluated by one way, ANOVA followed by Dunnet ‘t’ test. 
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Oral Glucose Tolerance Test (OGTT) results have been expressed on Table No:II. 
Half hour after the glucose treatment, all the groups of animal blood glucose levels 
were significantly increased (74.5±3.863↑, 35.2±6.6905↑, 59.5±3.764↑ & 
65.58±3.762↑). The blood glucose levels were significantly decreased for ,  aqueous 
ethanolic extract of Berberis aristata200 & 400 mg/kg (59.5±3.764↓& 65.58±3.762↓ 
) ↓), (P<0.001) **& (P<0.0001) ** when compared to control and positive control at 
1hour and each and every ½ hour blood glucose levels(200 mg/kg : 8.8±3.26,10±0, 
6.66±1.164 & 3±0.696, 400 mg/kg:17.9±1.422,9.97±0,14.7±1.093&5±0.696) 
(P<0.05)*, (P<0.001)**&  (P<0.0001)***  were changes in the dose dependent 
manner extract treated group of animals compared to control and positive control but 
400mg/kg produce the equipotent activity. 
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8. DISCUSSION 
Invitro study is on the principle of Inhibition of α-amylase, enzyme that plays 
a role in digestion of starch and glycogen are considered  a  strategy  for  the  
treatment  of  disorders  in  carbohydrate uptake,  such  as diabetes.  Pancreatic α-
amylase   is a key enzyme in the digestive system and catalyses the initial step in 
hydrolysis of starch to a mixture of smaller. Sequential extraction was done 
according to increasing polarity order (Petrolium ether,Ethyl acetate and 
Ethanol). Each extracts were tested for α-amylase inhibition to get the extraction with 
minimum IC50 value.  As per the above mechanism all the extract have concentration 
dependent affinity towards the inhibition of α-amylase. Finally ethanolic extract was 
observed as more active extract. LC-MS is a hyphenated technique, combining the 
separation power of HPLC, with the detection power of mass spectrometry. Even 
with a very sophisticated MS instrument, HPLC is still useful to remove the 
interferences from the sample that would impact the ionization. Closely related to 
LC-MS are some other techniques, like flow injection/MS, CE or CEC/MS, 
capillary LC or Nano LC-MS In all cases, there is the need for an interface that will 
eliminate the solvent and generate gas phase ions, then transferred to the optics of 
the mass spectrometer. Most instruments now atmospheric pressure ionization 
(API) technique where solvent elimination and ionization steps are combined in the 
source and take place at atmospheric pressure. When electron impact ionization 
(EI) is the choice, the solvent elimination and ionization steps are separate. Present 
study I have been used LC-MS for isolate and characterize the antidiabetic active 
compounds from extract.  LC-MS for most active extract was taken and 
bioinformatics was collected by PASS. PASS is the computer generated program 
which provides the simultaneous prediction of several hundreds of biological activity 
types for any drug-like compounds. In this bio informatics software prediction is 
based on the analysis of structure-activity relationships of (SAR) the training set 
including more than 30000 known biologically active compounds .The most active 
antidiabetic constituent in the ethanolic extract of Berberis aristatawas confirmed as 
Quercetin and other antidiabetic active constituent was confirmed as Kaempferol. In  
this  present  study  Acute  toxicity  study  was    carried  out  in  rats.  The procedure 
was followed by using OECD 423 (Acute Toxic Class Method). The acute toxic 
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class method is a step wise procedure with three animals of a single sex per step. 
Average  two to three steps  may  be necessary.  The method used to defined 
doses (2000, 1000, 500, 50, 5 mg/kg body weight, Up-and-Down Procedure). The 
starting dose level of EEKAGA was 2000 mg/kg body weight p.o as most of the 
crude extracts posses LD50 value more than 2000 mg/kg p.o and also found to be the 
maximum safe dose. Observe for signs for toxicity and were noted for 14 days. The 
onset of toxicity and signs of toxicity also noted. Hence, 1/10th (200mg/kg) and 
1/5th (400mg/kg) of this dose were selected for further study.The principle involved 
in the alloxan induced diabetes mellitus in rats, Alloxan,  a beta cytotoxic, diabetes 
induced chemical but wide variety of animal  species  by damaging  the insulin  
secreting  cells  of the pancreas.  Literature sources indicate that the  alloxan 
induced rats  are  hyperglycaemic.  The treatment of lower doses of alloxan  
(100mg/kg  b.w.)  produced  partial  destruction  of pancreatic  β-cells  even though 
the animals become permanently diabetic. Thus these animals have surviving β-
cells and regeneration is possible. It is well known that the sulfonylurea’s act by 
directly stimulating the β-cells of the islets of Langerhans to release more insulin and 
these compounds are active in mild alloxan induced diabetes. Invivo anti diabetic 
screening was performed for the confirmation of above mechanism of action was 
undergone the ethanolic extract of Berberis aristatain biological system (Wich was 
already resulted for  α-amylase inhibitory activity by Invitro and constituents 
analysis by LCMS methods). At the end of the the ethanolic extract of Berberis 
Aristata.(200  mg/kg  p.o,  400  mg/kg  p.o.)    showed statistically significant   
decrease  in  blood  glucose levels. So the ethanolic extract of Berberis aristata 
showed antidiabetic activity. This work will be useful for further diabetes mellitus 
and it’s related diseases research worker to develop new entity for the treatment of 
diabetes mellitus. 
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9. CONCLUSION 
   Extraction of leaf was done by sequential extraction method The leaves of 
Berberis aristata using the solvent with increasing polarity order ( petroleum ether, 
ethyl acetate and ethanol) and the active extract was tested by invitro antidiabetic 
screening method. The invitro antidiabetic study have been performed based on the α-
amylase inhibition assay. Each extracts were tested for α-amylase inhibition and the 
extract with minimum IC50 have been undergone phyto chemical screening. The 
preliminary phytochemical tests was performed to identify the active phytochemicals 
present in the ethanolic extract of Berberis aristata and showed the presence of 
Phenols, Flavanoids, Alkaloids, Glycosides, Saponins and Terpenoids. LCMS 
analysis and PASS (bioinformatic software) was performed four compounds were 
found out Kaempferol, Rhamnetin, Rhamnoxanthin, Quercetin and luteolin. The 
antidiabetic constituents were found to be Quercetin (more active) and Kaempferol 
(less active). Finally the invivo antidiabetic activity of Ethanolic extract of Berberis 
aristata leaf was tested by using alloxan induced diabetic rat. Acute toxicity study 
was carried out in rats. The procedure was followed by OECD 423(Acute toxicity 
class method).1/10th  (200mg/kg)and 1/5th (400mg/kg)of the maximum safe dose 
(2000mg/kg)were selected for further study. Fasting blood sample were drawn from 
retino orbital puncture of rats at weekly intervals till the end of the study 1,7 and 14 
days. On these days fasting blood glucose were collected and and analysed for 
glucose. At the end of the study (14th day)the ethanolic extract of Berberis aristata 
leaf (200mg/kg p.o and 400 mg/kg p.o) treated diabetic groups showed statistically 
significant decrease in blood glucose similar to the standard drug glibenclamide 
(2mg/kg), which indicated block the alfa amyalase activity and antagonize the 
alloxan action.The present study suggested that the isolation of active constituents 
from ethanolic extract of Berberis aristata leaf and characterize the compounds by 
using preliminary phytochemical studies and LCMS instrument used to isolate the 
compounds like Quercetin and Kaemferol were confirmed by confirmatory chemical 
tests. 
 
 
  
Department of Pharmacology                        46             J.K.K. Nattraja College Of Pharmacy    
 
 
10. BIBILIOGRAPHY 
 
1. KD Tripathi MD,. 2006.  Essential of medical pharmacology sixth edition. 
 
2. American Diabetes Association Revised Fall,. 2009. Diabetes Care. Jan 
2010; 33(Suppl 1):     S62–S69.  
 
3. Global health risks. Mortality and burden of disease attributable to selected major 
risks. Geneva, World Health Organization,2009. 
 
4. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ,. 2011. 
National, regional, and global trends in fasting plasma glucose and diabetes 
prevalence since 1980: systematic analysis of health examination surveys and 
epidemiological studies with 370 country-years and 
2.7millionparticipants. Lancet,,378(9785). 
 
5. Mathers CD, Loncar D. Projections of global mortality and burden of disease from,. 
2002. to 2030. 2006, PLoS Med, 3(11):e442. 
 
6. Global status report on noncommunicable diseases 2010. Geneva, World Health 
Organization, 2011.7. Pranav K. Prabhakar and Mukesh Doble,. 2008.  A Target Based 
Therapeutic Approach Towards Diabetes Mellitus UsingMedicinal Plants 
Bentham Science Publishers Ltd. Current Diabetes Reviews. 
 
8. National institute of diabetes and digestive and kidney deseases ,National Diabetes 
Information Clearinghouse (NDIC) review 2009 
 
9. Shigeyuki Kawa , Masahiro Maruyama and Takayuki Watanabe,. 2013.Prognosis 
and Long Term Outcomes of Autoimmune Pancreatitis  ;Version 1.0, 
November 8,  
 
  
Department of Pharmacology                        47             J.K.K. Nattraja College Of Pharmacy    
 
 
10.  Wang T.J., Larson M.G., Vasan R.S., Cheng S., Rhee E.P and McCabe E,. 2011.  
Metabolite profiles and the risk of developing diabetes. Nat Med. 
11.Young K.A., Snell-Bergeon J.K., Naik R.G., Hokanson J.E., Tarullo D and 
Gottlieb P.A., 2011. Vitamin D deficiency and coronary artery calcification in 
subjects with type 1 diabetes. Diabetes Care. 
 
12. Joergensen C., Hovind P., Schmedes A., Parving H.H and Rossing P.,2011 
Vitamin d levels, microvascular complications, and mortality in type 1 diabetes. 
Diabetes Care.;34(5). 
 
13. Kohei KAKU.,2010., Pathophysiology of Type 2 Diabetes and Its Treatment 
Policy JMAJ  
 
14. American Diabetes Association. Standards of medical care in 
diabetes.,2012. Diabetes Care. 2012;35(Supp 1) 
 
15. The International Expert Committee. International Expert Committee., 2009.the 
role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 
  
16. David b. sacks,Mark Arnold,George, Bakris,david e. bruns,Andrea rita Horvath, 
Kirkman and Ake lernmark2011,Guidelines and Recommendations for Laboratory 
Analysis in the Diagnosis and Management of Diabetes Mellitus Diabetes Care 
34:e61–e99 
 
17. Ronald J. Sigal, MD, MPH123,Glen P. Kenny, PHD23,David H.Wasserman., 
2006 .Physical Activity/Exercise and Type 2 Diabete A consensus statement from the 
American Diabetes Association , Diabetes Care  vol. 29 no. 6 1433-1438  
 
18. Jane borchers.,2009. Nutrition and lifestyle recommendations for people with pre-
diabetes  
      vol. 5 no324-45  
 
  
Department of Pharmacology                        48             J.K.K. Nattraja College Of Pharmacy    
 
 
19. Yki-JarvinenH.,2001.Combination therapies with insulin in type2 diabetes. 
Diabetic care. 
 
20. Jay W. Marks, MD ., 2000. EA.New hypoglucemic therapies-J R Coll Physicians 
Lond. 
 
21. Omudhome Ogbru., 2014 Insulin for Diabetes Treatment: Types, Side Effects, and 
PreparationsPharmacy  
 
22. jack deRuiter 2005, Overview of the antidiabetic agents Endocrine 
Pharmacotherapy Module, Spring,  
 
23. Bassam Abdul Rasool Hassan ., 2012.Medicinal Plants (Importance and Uses), 
3:10  
 
24. Hui Tag, P. Kalita, P. Dwivedi, A.K. Das and Nima D Namsa,2012. Herbal 
medicines used in the treatment of diabetes mellitus in Arunachal Himalaya, 
northeast, India Volume 141, Issue 3, 14 J, Pages 786–795  
 
25. Philip J Tuso, MD, FACP 2002, The Herbal Medicine Pharmacy Update The 
Permanente Journal/ Fall / Volume 6 No. 4 
 
26. Ikuo Nishida.,2005 Journal of Plant Research ISSN: 0918-9440 ,  
ISSN: 1618-0860 (electronic version)Journal. 
27. Andreana L.ososki,patricia lohr,marian reiff,micheal j.balick,fredi Kronenberg 
and Adriane fugh-berman,bonnie o’cornor.,2002. Ethnobotanical literature survey of 
medicinal plants in the Dominican republic used for women’s health condition. 
 
28. S.Dasgupta, a.parmar1 and h.patel.,2013. International Journal of Pharma and Bio 
Sciences Preliminary phytochemical studies of elaeocarpus variabilis Int J Pharm Bio 
Sci  4(4). 
  
Department of Pharmacology                        49             J.K.K. Nattraja College Of Pharmacy    
 
 
 
29. Isaac J. Asiedu-Gyekye  , Daniel A. Antwi,  Charles Awortwe , Benoit Banga 
N'guessan and Alexander K. Nyarko., 2007.Short-term administration of an aqueous 
extract of elaeocarpus variabilis. 
 
30. Cruz, E.A.; Reuter, S.; Martin, H.; Dehzad, N.; Muzitano, M.F.; Costa, S.S.;Rossi-
Bergmann, B.; Buhl, R.; Stassen and M.; Taube.,2012 C.Phytomedicine: International 
Journal of Phytotherapy & Phytopharmacology. 
 
31. Shazid M. Sharker, Mohammad K. Hossain, Mohammad R. Haque, Abu A. 
Chowdhury, Md. A. Kaisar, Choudhury M Hasan and Mohammad A. Rashid., 2012 
Asian Pacific Journal of Tropical Biomedicine. 
 
32. Patil SB, Dongare VR, Kulkarni CR, Joglekar MM and Arvindekar AU., 2013 
Antidiabetic activity of Elaeocarpus variabilis in streptozotocin-induced diabetic rats 
by glucose independent insulin secretagogue action. 
 
33. Gad MZ, El-Sawalhi MM, Ismail MF and El-Tanbouly ND., 2006. Biochemical 
study of the anti-diabetic action of the Egyptian plants fenugreek and balanites. 
 
34. Swapnil B. Patil, Vandana R. Dongare, Chaitanya R. Kulkarni, Madhav M. 
Joglekar, and Akalpita U. Arvindekar.,2013. Antidiabetic activity of Elaeocarpus 
variabilis in streptozotocin-induced diabetic rats by glucose independent insulin 
secretagogue action. 
 
35. Dzhafarova RE, Garaev GSh and Dzhafarkulieva ZS ., 2009 . Antidiabetic action 
of extract of Juglans regia. 
 
36. S. Radhika, Vel Sri Ranga Sanku, K.H. Smila and R. Muthezhilan., 2011. 
Antidiabetic and Hypolipidemic Activity of Punica granatum Linn on Alloxan 
Induced Rats World Journal of Medical Sciences. 
 
  
Department of Pharmacology                        50             J.K.K. Nattraja College Of Pharmacy    
 
 
37. Ishtiaq Ahmed, Saif-Ur-Rehman, Saghir Ahmad Jafri, Sajid Hassan,Ishtiaq 
Ahmed and Muhammad Naim ., 2011. Antidiabetic Effect of Aloe vera Extract on 
Alloxan Induced Diabetic Rats, Libyan Agriculture Research Center Journal 
International. 
38. Kuroda M, Mimaki Y, Nishiyama T, Mae T, Kishida H, Tsukagawa M, Takahashi 
K, Kawada T, Nakagawa K and  Kitahara M .,2005, Hypoglycemic effects of turmeric 
(Curcuma longa L. rhizomes) on genetically diabetic KK-Ay mice. 
 
39.  Mondal, Susanta Kumar ; Chakraborty, Goutam ; Bhaumik, Uttam Kumar ; 
Gupta, Malaya ; Mazumder, Upal and Kanti., 2008.  Antidiabetic activity of 
Diospyros malabarica Kostel bark: a preliminary investigation for possible mode of 
action, Oriental pharmacy and experimental medicine. 
 
40. Grover JK, Yadav.S and Vats V  J., 2002.   Medicinal plants of India with anti-
diabetic potential,Ethnopharmacol. 
 
41. Rajnish Gupta and R. S. Gupta.,2011.Antidiabetic efficacy of mangifera indica 
seed kernels in rats: a comparative study with glibenclamide,  Diabetologia Croatica. 
 
42. Sabjan Khaleel Basha and Vinoji Sugantha Kumari.,2012. In vitro antidiabetic 
activity of psidium guajava leaves extracts  Asian Pacific Journal of Tropical Disease 
S98-S100. 
 
43. Yoshino K, Miyauchi Y, Kanetaka T, Takagi Y, Koga K., 2009. Anti-diabetic 
activity of a leaf extract prepared from Salacia reticulata in mice.73(5):1096-104.  
 
44. Akhani SP, Vishwakarma SL and Goyal RK., 2004; Anti-diabetic activity of 
Zingiber officinale in streptozotocin-induced type I diabetic rats,56(1):101-5. 
 
45. Ramadan KS, Khalil OA, Danial EN, Alnahdi HS,and  Ayaz NO., 2013.; 
Hypoglycemic and hepatoprotective activity of Rosmarinus officinalis extract in 
diabetic rats 69(4):779-83.  
  
Department of Pharmacology                        51             J.K.K. Nattraja College Of Pharmacy    
 
 
 
46.Noncommunicable Diseases in the Southeast Asia Region, Situation and Response, 
World Health Organization, 2011.  
 
47.David R. Whiting.,2011. Global estimates of the prevalence of diabetes for 2011 
and 2030, Diabetes Research and Clinical Practice, Volume 94, Issue 3, Pages 311-
321. 
 
48. Anjana RM, Pradeepa R, Deepa M, Datta M, Sudha V and Unnikrishnan R, 2013 
“Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired 
glucose tolerance) in urban and rural India. phase I results of the Indian Council of 
Medical Research-India Diabetes (ICMR-INDIAB) study” Diabetologi: a 54.12 
(2011): 3022-7. NCBI. 
 
49.Wunderlin,R.P and B.F..Hansen.,2008. Atlas of florida vascular plants,Institute of 
Systematic Botany ,FL literature en.hortipedia.com/wiki/Elaeocarpus 
variabilis_elaeocarpus variabilis. 
 
50. Michael j. Balick, Fredi kronenberg, Andreana l. Ososki,Marian reiff, Adriane 
fugh-berman, Bonnie o’connor,Maria roble, Patricia lohr, and Daniel atha., 
2000.Medicinalal plants used by latino healers for women’shealth conditions in new 
medicinyork city1 Economic Botany. 
 
51..Thalapanani N ,Chidambaram   KA,Ellappan T,Sabapati ML and Mandal 
SC.,2008..Journel of complimentary and Integrative medicine. 
 
52. Hedari R,Zareae and S,Heidarizadesh M., 2005. Journel of Nutrion. 
 
53. Tonack S,Neoptolemos and JP,Costello E.,2010.Analysis of serum proteins by 
LC-MS/MS Methods, Mol Biol. 
 
  
Department of Pharmacology                        52             J.K.K. Nattraja College Of Pharmacy    
 
 
54. Gloriozova,T.A Filimonov,D.A.Lagunin and A.A.Poroikov,V.,1998.Evaluation 
of computer system for prediction of biological activity PASS on the set of new 
chemical compounds.Chim.-Pharm.J.(Rus). 
 
55.Milne G.W.A and Miller. J.A.,1986.The information System,System 
overview,JCheminf.comput.sci. 
 
56.Voigt J.H,Bienfait B,Wang S and Nicklaus M.C. .,2001.Comparison of NCI Open 
Database with even Large Chemical Structural Database,J.Chem.Inf Comput Sci. 
 
57. Diabetes Blue Circle Symbol,17 March 2006. International DIABETES 
Federation. 
 
58 .Ihlenfeldt.WD,Voigt J.H Bienfait.B,Oellien.F and Nicklaus.MC.,2002.Enhanced 
CACTVS Browser of the open NCI Database,j chem..inf,comput,sci. 
 
59.http://www.OECD.com 
